lofacimig

Lofacimig (KN060) is an investigational monoclonal antibody that acts as a selective inhibitor of activated Factor XI (Factor XIa). By inhibiting Factor XIa, it aims to reduce the risk of blood clot formation without significantly increasing bleeding risk. The drug is being developed primarily for the prevention of venous thromboembolism (VTE), especially in patients undergoing total knee arthroplasty and other settings where thrombosis risk is elevated. Clinical trials are ongoing in China, with Phase 2 studies comparing its efficacy and safety to enoxaparin for VTE prevention after orthopedic surgery. Lofacimig is administered intravenously[1][4][7].